Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Ernest Adeghate, Sahar Mohsin, Faisal Adi, Fares Ahmed, Ali Yahya, Huba Kalász, Kornelia Tekes & Ernest A. Adeghate. (2019) An update of SGLT1 and SGLT2 inhibitors in early phase diabetes-type 2 clinical
trials. Expert Opinion on Investigational Drugs 28:9, pages 811-820.
Read now
Read now
A. Avogaro, A. Giaccari, P. Fioretto, S. Genovese, F. Purrello, F. Giorgino & S. Del Prato. (2017) A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus. Expert Review of Clinical Pharmacology 10:7, pages 763-772.
Read now
Read now
Vasilios Tsimihodimos, Theodosios D. Filippatos & Moses S. Elisaf. (2017) Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies. Expert Opinion on Drug Metabolism & Toxicology 13:4, pages 399-408.
Read now
Read now
Paola Fioretto & Angelo Avogaro. (2017) Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes. Expert Opinion on Pharmacotherapy 18:5, pages 517-527.
Read now
Read now
Articles from other publishers (28)
Adrian Liew, Aida Lydia, Bien J. Matawaran, Paweena Susantitaphong, Huong Thi Bich Tran & Lee Ling Lim. (2023)
Practical considerations for the use of
SGLT
‐2 inhibitors in the
A
sia–
P
acific countries—An expert consensus statement
. Nephrology 28:8, pages 415-424.
Crossref
Crossref
Xi Rong, Yawen Zhu, Bo Wen, Kai Liu, Xinran Li, Qiling Gou & Xiaoping Chen. (2022) Risk of hypovolemia associated with sodium–glucose cotransporter-2 inhibitors treatment: A meta-analysis of randomized controlled trials. Frontiers in Cardiovascular Medicine 9.
Crossref
Crossref
Daisuke Sato, Takao Nakamura, Jota Amarume, Mizuna Yano, Atsuyoshi Nishina, Zhonggang Feng & Masataka Kusunoki. (2022) Effects of dapagliflozin on peripheral sympathetic nerve activity in standard chow- and high-fat-fed rats after a glucose load. Journal of Pharmacological Sciences 148:1, pages 86-92.
Crossref
Crossref
Pierre Delanaye & Andre J. Scheen. (2021) The diuretic effects of SGLT2 inhibitors: A comprehensive review of their specificities and their role in renal protection. Diabetes & Metabolism 47:6, pages 101285.
Crossref
Crossref
Min-Kyung Lee, Bongsung Kim, Kyungdo Han, Jae-Hyuk Lee, Minhee Kim, Mee Kyoung Kim, Ki-Hyun Baek, Ki-Ho Song, Hyuk-Sang Kwon & Young-Jung Roh. (2021) Sodium–Glucose Cotransporter 2 Inhibitors and Risk of Retinal Vein Occlusion Among Patients With Type 2 Diabetes: A Propensity Score–Matched Cohort Study. Diabetes Care 44:10, pages 2419-2426.
Crossref
Crossref
Hajime Kataoka & Yuichi Yoshida. (2020) Enhancement of the serum chloride concentration by administration of sodium–glucose cotransporter-2 inhibitor and its mechanisms and clinical significance in type 2 diabetic patients: a pilot study. Diabetology & Metabolic Syndrome 12:1.
Crossref
Crossref
Weihao Wang, Lina Zhang, Xiaobei Pei, Qi Pan & Lixin Guo. (2020) Evaluation of the safety of sodium‐glucose co‐transporter‐2 inhibitors for treating patients with type 1 diabetes. Diabetes, Obesity and Metabolism 22:10, pages 1767-1776.
Crossref
Crossref
Joaquim Silva CustódioJrJr, Jarbas Roriz-Filho, Catarina Addobbati Jordão Cavalcanti, Amanda Martins & João Eduardo Nunes Salles. (2020) Use of SGLT2 Inhibitors in Older Adults: Scientific Evidence and Practical Aspects. Drugs & Aging 37:6, pages 399-409.
Crossref
Crossref
Eiichi Araki, Hirotaka Watada, Yasuko Uchigata, Osamu Tomonaga, Hitomi Fujii, Hiroshi Ohashi, Tadashi Okabe, Michiko Asano, Fredrik Thoren, Hyosung Kim, Toshitaka Yajima & Anna Maria Langkilde. (2019) Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT‐5): 52‐week results from a randomized, open‐label, phase III clinical trial. Diabetes, Obesity and Metabolism 22:4, pages 540-548.
Crossref
Crossref
In Hee Lee & Dong Jik Ahn. (2020) Dapagliflozin-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes mellitus. Medicine 99:21, pages e20228.
Crossref
Crossref
Maria Mirabelli, Eusebio Chiefari, Patrizia Caroleo, Raffaella Vero, Francesco Saverio Brunetti, Domenica Maria Corigliano, Biagio Arcidiacono, Daniela Patrizia Foti, Luigi Puccio & Antonio Brunetti. (2019) Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus. Journal of Diabetes Research 2019, pages 1-8.
Crossref
Crossref
Fang-Hong Shi, Hao Li, Long Shen, Zhen Zhang, Yi-Hong Jiang, Yao-Min Hu, Xiao-Yan Liu, Zhi-Chun Gu, Jing Ma & Hou-Wen Lin. (2019) Appraisal of Non-Cardiovascular Safety for Sodium–Glucose Co-Transporter 2 Inhibitors: A Systematic Review and Meta-Analysis of Placebo-Controlled Randomized Clinical Trials. Frontiers in Pharmacology 10.
Crossref
Crossref
Gabriel Helmlinger, Victor Sokolov, Kirill Peskov, Karen M. Hallow, Yuri Kosinsky, Veronika Voronova, Lulu Chu, Tatiana Yakovleva, Ivan Azarov, Daniel Kaschek, Artem Dolgun, Henning Schmidt, David W. Boulton & Robert C. Penland. (2019) Quantitative Systems Pharmacology: An Exemplar Model‐Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development. CPT: Pharmacometrics & Systems Pharmacology 8:6, pages 380-395.
Crossref
Crossref
Habib Yaribeygi, Stephen L. Atkin & Amirhossein Sahebkar. (2019) Mechanistic effects of SGLT2 inhibition on blood pressure in diabetes. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 13:2, pages 1679-1683.
Crossref
Crossref
Julio Rosenstock, Chantal Mathieu, Hungta Chen, Ricardo Garcia-Sanchez & Gabriela Luporini Saraiva. (2018) Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin. Archives of Endocrinology and Metabolism 62:4, pages 424-430.
Crossref
Crossref
Hao Li, Fang-Hong Shi, Shi-Ying Huang, Shun-Guo Zhang & Zhi-Chun Gu. (2018) Clinical adverse effects of sodium-glucose cotransporter 2 inhibitors. Medicine 97:32, pages e11853.
Crossref
Crossref
Sergio Dellepiane, Moufida Ben Nasr, Emma Assi, Vera Usuelli, Teresa Letizia, Francesca D’Addio, Gian Vincenzo Zuccotti & Paolo Fiorina. (2018) Sodium glucose cotransporters inhibitors in type 1 diabetes. Pharmacological Research 133, pages 1-8.
Crossref
Crossref
Hiddo J.L. Heerspink, Mikhail Kosiborod, Silvio E. Inzucchi & David Z.I. Cherney. (2018) Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney International 94:1, pages 26-39.
Crossref
Crossref
Takahiro Okumura & Toyoaki Murohara. (2018) Are Sodium-Glucose Cotransporter 2 Inhibitors Really Useful and Safe for Advanced Heart Failure?. Circulation Journal 82:7, pages 1752-1753.
Crossref
Crossref
Serge Jabbour, Jochen Seufert, Andre Scheen, Clifford J. Bailey, Cathrina Karup & Anna M. Langkilde. (2018) Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials. Diabetes, Obesity and Metabolism 20:3, pages 620-628.
Crossref
Crossref
Cristina Bianchi, Giuseppe Daniele, Angela Dardano & Stefano Del Prato. 2018. Diabetes Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment. Diabetes Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment
527
569
.
Cristina Bianchi, Giuseppe Daniele, Angela Dardano & Stefano Del Prato. 2018. Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment. Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment
1
44
.
Georg Gelbenegger, Nina Buchtele, Christian Schoergenhofer, Martin Roeggla & Michael Schwameis. (2017) Severe Hypernatraemic Dehydration and Unconsciousness in a Care-Dependent Inpatient Treated with Empagliflozin. Drug Safety - Case Reports 4:1.
Crossref
Crossref
Huilin Tang, Dandan Li, Jingjing Zhang, Yufeng Li, Tiansheng Wang, Suodi Zhai & Yiqing Song. (2017) Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials. Diabetes, Obesity and Metabolism 19:8, pages 1106-1115.
Crossref
Crossref
Eiichi Araki, Yukiko Onishi, Michiko Asano, Hyosung Kim & Toshitaka Yajima. (2017) Efficacy and safety of dapagliflozin over 1 year as add-on to insulin therapy in Japanese patients with type 2 diabetes: the DAISY (Dapagliflozin Added to patients under InSulin therapY) trial. Diabetes, Obesity and Metabolism 19:4, pages 562-570.
Crossref
Crossref
Andrew McGovern, Michael Feher, Neil Munro & Simon de Lusignan. (2017) Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use. Diabetes Therapy 8:2, pages 365-376.
Crossref
Crossref
Lee-Shing Chang & Matthew I. Kim. (2016) Antiglycemic Agents. Hospital Medicine Clinics 5:4, pages 542-554.
Crossref
Crossref
Genjiro Kimura. (2016) Diuretic Action of Sodium-Glucose Cotransporter 2 Inhibitors and Its Importance in the Management of Heart Failure. Circulation Journal 80:11, pages 2277-2281.
Crossref
Crossref